Bushal Chemi-Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 08-12-2024
- Paid Up Capital ₹ 4.96 Cr
as on 08-12-2024
- Company Age 42 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.10 M
as on 08-12-2024
- Revenue -16.61%
(FY 2024)
- Profit 22.72%
(FY 2024)
- Ebitda -26.32%
(FY 2024)
- Net Worth 12.78%
(FY 2024)
- Total Assets -7.55%
(FY 2024)
About Bushal Chemi-Pharma
The Corporate was formerly known as Hema Chem Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.96 Cr.
The company currently has active open charges totaling ₹2.10 M.
Shobha Thopte, Pooja Thopte, and Siddhesh Mande serve as directors at the Company.
- CIN/LLPIN
U24114MH1982PTC027012
- Company No.
027012
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 1982
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bushal Chemi-Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Siddhesh Mande  | Director | 23-May-2016 | Current |
| Shobha Thopte | Director | 19-Jan-2008 | Current |
| Pooja Thopte | Director | 01-Apr-2008 | Current |
Financial Performance of Bushal Chemi-Pharma.
Bushal Chemi-Pharma Private Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 16.61% decrease. The company also saw a substantial improvement in profitability, with a 22.72% increase in profit. The company's net worth Soared by an impressive increase of 12.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bushal Chemi-Pharma?
In 2023, Bushal Chemi-Pharma had a promoter holding of 6.86% and a public holding of 93.14%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bushal Health Care Private LimitedActive 24 years 13 daysShobha Thopte and Pooja Thopte are mutual person
Bushal Laboratories Private LimitedActive 36 years 9 monthsShobha Thopte and Pooja Thopte are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Oct 2023 | ₹1.10 M | Open |
Others Creation Date: 06 Mar 2021 | ₹1.00 M | Open |
How Many Employees Work at Bushal Chemi-Pharma?
Bushal Chemi-Pharma has a workforce of 47 employees as of Nov 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bushal Chemi-Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bushal Chemi-Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
